MA50174A - Formules de protéines de fusion vegfr-fc - Google Patents

Formules de protéines de fusion vegfr-fc

Info

Publication number
MA50174A
MA50174A MA050174A MA50174A MA50174A MA 50174 A MA50174 A MA 50174A MA 050174 A MA050174 A MA 050174A MA 50174 A MA50174 A MA 50174A MA 50174 A MA50174 A MA 50174A
Authority
MA
Morocco
Prior art keywords
vegfr
fusion protein
protein formulas
formulas
fusion
Prior art date
Application number
MA050174A
Other languages
English (en)
Inventor
Robert Matthew Fesinmeyer
Monica Michelle Goss
Sekhar Kanapuram
Rahul Rajan Kaushik
Sai Chakradhar Padala
Yael Wexler-Cohen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA50174A publication Critical patent/MA50174A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
MA050174A 2017-09-18 2018-09-17 Formules de protéines de fusion vegfr-fc MA50174A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762559987P 2017-09-18 2017-09-18
US201862618910P 2018-01-18 2018-01-18

Publications (1)

Publication Number Publication Date
MA50174A true MA50174A (fr) 2020-07-29

Family

ID=63794648

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050174A MA50174A (fr) 2017-09-18 2018-09-17 Formules de protéines de fusion vegfr-fc

Country Status (4)

Country Link
US (2) US20200255496A1 (fr)
EP (1) EP3684332A1 (fr)
MA (1) MA50174A (fr)
WO (1) WO2019055902A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
AU2019212622A1 (en) 2018-01-26 2020-08-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (fr) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Formulations aqueuses stables d'aflibercept
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CA2466034C (fr) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Formulations pharmaceutiques aqueuses stables d'anticoprs daclizumab
EA200870264A1 (ru) * 2006-02-15 2009-02-27 Имклоун Системз Инкорпорейтед Композиция антител
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP2944306B1 (fr) 2006-06-16 2021-01-27 Regeneron Pharmaceuticals, Inc. Formulations antagonistes vegf appropriées pour l'administration intravitréenne
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
WO2017129685A1 (fr) 2016-01-26 2017-08-03 Formycon Ag Formulation liquide d'un antagoniste du vegf
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途

Also Published As

Publication number Publication date
WO2019055902A1 (fr) 2019-03-21
EP3684332A1 (fr) 2020-07-29
US20200255496A1 (en) 2020-08-13
US20230025418A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
MA51291A (fr) Protéines de fusion il-2 fc modifiées
DK3292141T3 (da) Fusionsproteiner
DK3497117T3 (da) Nye alkalisk stabile immunglobulin-bindende proteiner
DK3197453T3 (da) Kimært protein
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
ES1243880Y (es) Cepillo de dientes
MA53616A (fr) Protéines bispécifiques modifiées
MA50174A (fr) Formules de protéines de fusion vegfr-fc
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
DK3723783T3 (da) Mitokondrie-målrettede peptider
DK3107562T3 (da) P97-ids-fusionsproteiner
CL2018000520A1 (es) Proteinas inhibidoras de insectos novedosas
DK3416974T3 (da) Proteinoprensning
DK3737403T3 (da) Modificerede adenovira
KR20180085041A (ko) 칫솔
DK3110837T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf
ZA202003845B (en) Fusion proteins
MA45684A (fr) Protéine d'apport du cerveau
MA50068A (fr) Formulations de copanlisib
ES2965775T3 (es) Procedimiento de fresado
DE112018001345A5 (de) Gelenkbeschlag
DK3574100T3 (da) Cellefrit proteinsyntesesystem
IT201700074265A1 (it) Occhiali
EP3649159C0 (fr) Protéine de fusion
DE102017206431A8 (de) Brillenbügel